Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: Could it be related to a different cytokine microenvironment?

Journal of Cutaneous Pathology

Volumn 34, Issue 4, 2007, Pages 301-308

  Moretti, Silvia ^a,b   Spallanzani, Adelina ^a   Pinzi, Cinzia ^a   Prignano, Francesca ^a   Fabbri, Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Department of Dermatological Sciences ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ELECTRON MICROSCOPY; FEMALE; FIBROGENESIS; FIBROSIS; HUMAN; MACROPHAGE; MALE; MELANOMA; MOLECULAR EVOLUTION; NEVUS; PHENOTYPE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MELANOMA; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; NEVUS, PIGMENTED; SKIN NEOPLASMS;

EID: 33947519009     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00616.x     Document Type: Article

References (23)

1. Rhodes AR. Neoplasms. benign neoplasias, hyperplasias, and dysplasias of melanocytes. In Fitzpatrick TB et al., eds. Dermatology in General Medicine, 4th ed. New York: McGraw-Hill Co., 1993; 1037.
2. Zeff RA, Freitag A, Gin CM, Grant-Kels JM. The immune response in halo nevi. J Am Acad Dermatol 1997; 37: 620.
3. Bodhurta AJ. Spontaneous regression of malignant melanoma. In Clark WH, Goldman L, Mastrangelo MJ, eds. Human Malignant Melanoma. New York: Grune & Stratton, 1979; 227.
4. High WA, Stewart D, Wilbers CR, Cockerell CJ, Hoang MP, Fitzpatrick JE. Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J Am Acad Dermatol 2005; 53: 89.
5. Schneeberger A, Koszik F, Stingl G. Immunological host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J Invest Dermatol 1995; 105: 110S.
6. Bodey B, Bodey B Jr, Siegel SE, Luck JV, Kaiser HE. Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes. Anticancer Res 1996; 16: 3439.
7. Bergman W, Willemze R, de Graaf-Reitsma C, Ruiter D. Analysis of major histocompatibility antigens and the mononuclear cell infiltrate in halo nevi. J Invest Dermatol 1985; 85: 25.
8. Akasu R, From L, Kahn H. Characterization of the mononuclear infiltrate involved in regression of halo nevi. J Cutan Pathol 1994; 21: 302.
9. Fernandez-Herrera J, Fernandez-Ruis E, Lopez-Cabrera M, Garcia Diez A, Sanchez-Madrid F, Gonzalez-Amaro R. CD69 expression and tumor necrosis factor-alpha immunoreactivity in the inflammatory infiltrate of halo naevi. Br J Dermatol 1996; 134: 388.
10. Tefany FJ, Barnetson R, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991; 97: 197.
11. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992; 20: 315.
12. Moretti S, Pinzi C, Spallanzani A et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer (Pred Oncol) 1999; 84: 160.
13. Graves DT, Barnhill R, Galanopoulos T, Antoniades HN. Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am J Pathol 1992; 140: 9.
14. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12: 547.
15. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanoma. J Invest Dermatol 1997; 108: 914.
16. Yasaka N, Furue M, Tamaki K. Histopathological evaluation of halo phenomenon in Spitz nevus. Am J Dermatopathol 1995; 17: 484.
17. Harvell JD, Meehan SA, Le Boit PE. Spitz's nevi with halo reaction: a histopathologic study of 17 cases. J Cutan Pathol 1997; 24: 611.
18. Scott G, Stoler M, Sarkar S, Halaban R. Localization of basic fibroblastic growth factor mRNA in melanocytic lesions by in situ hybridization. J Invest Dematol 1991; 96: 318.
19. Barnhill RL, Xiao M, Graves D, Antoniades HN. Expression of platelet-derived growth factor (PDGF-A, PDGF-B) and the PDGF-α receptor, but not the PDGF-β receptor, in human malignant melanoma in vivo. Br J Dermatol 1996; 135: 898.
20. Reed JA, McNutt NS, Prieto VG, Albino AP. Expression of transforming growth factor-β2 in malignant melanoma correlates with the depth of tumor invasion. Am J Pathol 1994; 145: 97.
21. Kinkhabwala M, Sehajpal P, Skolnik E et al. A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med 1990; 171: 941.
22. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblastic growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 1994; 144: 329.
23. al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edimburg 2000; 45: 1.